SGC-CBP30

Catalog No.S7256 Batch:S725603

Print

Technical Data

Formula

C28H33ClN4O3
Molecular Weight 509.04 CAS No. 1613695-14-9
Solubility (25°C)* In vitro DMSO 100 mg/mL (196.44 mM)
Ethanol 100 mg/mL (196.44 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM in cell-free assays, respectively. Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively.
Targets
CREBBP [1]
(Cell-free assay)		 EP300 [1]
(Cell-free assay)
21 nM 38 nM
In vitro

As a CREBBP/EP300-selective chemical probe, SGC-CBP30 shows moderate cytotoxicity in U2OS cells and HeLa cells.

Features CREBBP/EP300-selective chemical probe.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    COLO-320-HSR cells

  • Concentrations

    20 μM

  • Incubation Time

    6 h

  • Method

    Cells were then treated for 6 hours with 20μM SGC-SCP30 or DMSO.
Animal Study:

[3]
  • Animal Models

    Sprague-Dawley rats

  • Dosages

    25 mg/kg

  • Administration

    p.o.

References

  • http://www.thesgc.org/chemical-probes/CBP30
  • https://pubmed.ncbi.nlm.nih.gov/34819668/
  • https://pubmed.ncbi.nlm.nih.gov/30119248/

Customer Product Validation

H3K27ac change. SMMC-7721 cells were treated with EPZ-6438 (1 μM) alone or in combination with histone acetyltransferase inhibitors C646 (5 μM) or SGC-CBP30 (5 μM) for 6 days. H3K27ac was examined by immunoblotting.

Data from [ , , Cell, 2018, 175(1):186-199 ]

Immuno-blot analysis of protein crotonylation after NaCr treatment in the absence or presence of p300/CBP inhibitors.

Data from [ , , J Proteome Res, 2017, 16:1743−1752 ]

Combination of DDR1 and EP300 inhibitors synergistically alleviated BLM-induced pulmonary fibrosis and inflammation in vivo. Except for rats in the normal group, all rats were pre-treated with 2.5 U/Kg bleomycin at day 0, and were orally administrated CQ-061 (50 mg/kg) and/or SGC-CBP30 (25 mg/Kg) or normal saline (NS) once per day for 14 days (from days 1–14). At the 15th day of bleomycin injection, all rats were sacrificed, BALF were collected, and lung tissues were sectioned and subjected to H&E staining.

Data from [ , , Biomed Pharmacother, 2018, 106:1727-1733 ]

Selleck's SGC-CBP30 Has Been Cited by 40 Publications

CBP Bromodomain Inhibition Rescues Mice From Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses [ Frontiers in Immunology, February 2, 2021, 625542] PubMed: 33603756
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells [ Clinical Cancer Research, April 1, 2021, 2087-2099] PubMed: 33495313
Hypoxia-induced phase separation of ZHX2 alters chromatin looping to drive cancer metastasis [ Mol Cell, 2025, 85(8):1525-1542.e10] PubMed: 40185097
Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis [ Cell Death Dis, 2025, 16(1):193] PubMed: 40113760
Identification of the core regulatory program driving NEUROD1-induced neuronal reprogramming [ Cell Rep, 2025, 44(4):115523] PubMed: 40173039
Noncoding RNA, ncRNA-a3, Epigenetically Regulates TAL1 Transcriptional Program During Erythropoiesis [ Mol Cell Biol, 2025, 45(4):169-184] PubMed: 40211453
NF-κB signaling directs a program of transient amplifications at innate immune response genes [ bioRxiv, 2025, 2025.03.11.641929] PubMed: 40161744
High-throughput discovery and characterization of viral transcriptional effectors in human cells [ Cell Syst, 2023, 14(6):482-500.e8] PubMed: 37348463
NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer [ Cell Rep, 2023, 42(8):112963] PubMed: 37561631
Chemical-induced epigenome resetting for regeneration program activation in human cells [ Cell Rep, 2023, 42(6):112547] PubMed: 37224020

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.